KOD Latest Press Releases

-- February 4, 2026 --

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 PRNewswire 7:00 AM

-- January 7, 2026 --

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference PRNewswire 8:20 PM

-- December 18, 2025 --

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares PRNewswire 8:27 PM

-- December 16, 2025 --

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock PRNewswire 10:55 PM

-- December 15, 2025 --

Kodiak Sciences Announces Proposed Public Offering of Common Stock PRNewswire 4:01 PM

-- November 13, 2025 --

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results PRNewswire 4:05 PM

-- November 12, 2025 --

Kodiak Sciences to Present at Upcoming Investor Conferences PRNewswire 5:48 PM

-- November 5, 2025 --

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (=90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) PRNewswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software